Strategies for biomarker development in psoriatic disease: A Report from the GRAPPA 2010 Annual Meeting

Journal of Rheumatology

Volumn 39, Issue 2, 2012, Pages 423-426

  Ritchlin, Christopher T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Biomarker; Psoriasis; Psoriatic arthritis; Psoriatic disease; Surrogate

Indexed keywords

BIOLOGICAL MARKER; CD16 ANTIGEN; DENDRITIC CELL SPECIFIC MEMBRANE PROTEIN; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ANXIETY DISORDER; ARTHRITIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; CONFERENCE PAPER; CORRELATION ANALYSIS; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; ENTERITIS; FLOW CYTOMETRY; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MEDICAL RESEARCH; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOCLAST; PATIENT CARE; PRIORITY JOURNAL; PROTEOMICS; PSORIASIS; PSORIATIC ARTHRITIS; RISK ASSESSMENT; UVEITIS;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; PSORIASIS;

EID: 84856534794     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111240     Document Type: Conference Paper

References (30)

1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
2. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011;124:775.e1-6.
3. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: Strength in numbers, part II. J Invest Dermatol 2011;131:1007-10.
4. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-6.
5. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res 2011;63:195-202.
6. FitzGerald O, Chandran V. Update on biomarkers in psoriatic arthritis: A report from the GRAPPA 2010 Annual Meeting. J Rheumatol 2012;39:427-30.
7. Rahman P, Elder JT. Genetics of psoriasis and psoriatic arthritis: A report from the GRAPPA 2010 Annual Meeting. J Rheumatol 2012;39:431-3.
8. Gladman DD, Ritchlin CT, FitzGerald O. The path forward to biomarker discovery in psoriatic disease: A report from the GRAPPA 2010 Annual Meeting. J Rheumatol 2012;39:434-6.
9. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
10. Pattison E, Harrison BJ, Griffiths CE, Silman AJ, Bruce IN. Environmental risk factors for the development of psoriatic arthritis: Results from a case-control study. Ann Rheum Dis 2008;67:672-6. (Pubitemid 351571932)
11. Ritchlin CT. GRAPPA trainees symposium 2010: A report from the GRAPPA 2010 Annual Meeting. J Rheumatol 2012;39:394-7.
12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
13. Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, et al. Biomarkers and personalised medicine in rheumatoid arthritis: A proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 2011;70:1713-8. Epub 2011 Jul 22.
14. Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol 2009;5:634-41.
15. Benton N, Stewart N, Crabbe J, Robinson E, Yeoman S, McQueen FM. MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years. Ann Rheum Dis 2004;63:555-61. (Pubitemid 38530200)
16. Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010;42:996-9.
17. Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009;5:83-91.
18. Batliwalla FM, Li W, Ritchlin CT, Xiao X, Brenner M, Laragione T, et al. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med 2005;11:21-9.
19. Stoeckman AK, Baechler EC, Ortmann WA, Behrens TW, Michet CJ, Peterson EJ. A distinct inflammatory gene expression profile in patients with psoriatic arthritis. Genes Immun 2006;7:583-91. (Pubitemid 44614873)
20. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31. (Pubitemid 37074957)
21. Chiu YG, Shao T, Feng C, Mensah KA, Thullen M, Schwarz EM, et al. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther 2010;12:R14.
22. Ritchlin CT, Proulx S, Schwarz ES. Translational perspectives on psoriatic arthritis. J Rheumatol Suppl 2009 Aug;83:30-4.
23. McGonagle D. Imaging the joint and enthesis: Insights into pathogenesis of psoriatic arthritis. Ann Rheum Dis 2005;64 Suppl 2:ii58-60. (Pubitemid 40288524)
24. Marzo-Ortega H, McGonagle D, Rhodes LA, Tan AL, Conaghan PG, O'Connor P, et al. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis 2007;66:778-81. (Pubitemid 46846697)
25. Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008;67:296-301. (Pubitemid 351281261)
26. Weber U, Maksymowych WP, Jurik AG, Pfirrmann CW, Rufibach K, Kissling RO, et al. Validation of whole-body against conventional magnetic resonance imaging for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondylarthritis. Arthritis Rheum 2009;61:893-9.
27. Gisondi P, Tinazzi I, El-Dalati G, Gallo M, Biasi D, Barbara LM, et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: A hospital-based case-control study. Ann Rheum Dis 2008;67:26-30.
28. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Carotid intima-media thickness in psoriatic arthritis: Differences between tumor necrosis factor-alpha blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011;31:705-12.
29. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA 2011;108:3731-6.
30. Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: Subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010;12:R113.